Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders and other rare diseases. The company’s pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.

Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries.